Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is well above the current analyst consensus estimate of $22.48, and suggests Wall Street’s fourth quarter expectations may be too low.

With a market cap of around $730 billion, Eli Lilly ( LLY 0.92%) is one of the largest pharmaceutical companies on planet Earth. It has a strong position in the emerging niche of weight loss drugs, with patent protections that extend into the mid-2030s. And there's a solid pipeline of drugs coming up, too.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. Learn more about LLY stock here.

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising full-year guidance.

Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors interested in healthcare stocks may be taking note of its consistent growth,

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on strong obesity drug momentum.